Disease Landscape and Forecast Insights

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…

Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

To determine the trade-offs across key biosimilar attributes that surveyed rheumatologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-based…

Abstract

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029…

In 2019, sales of branded MAb biologics in oncology exceeded $20 billion in the major pharmaceutical markets (United States, EU5, and Japan), and the sales of biosimilars in these regions totaled $…

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…